Data Sciences in Pharma - Patient Centered Outcomes Research

Data Sciences in Pharma - Patient Centered Outcomes Research

位教师：Susanne Clinch

访问权限由 Coursera Learning Team 提供

2,970 人已注册

4个模块

深入了解一个主题并学习基础知识。

22 条评论

中级等级

推荐体验

9 小时完成

灵活的计划

自行安排学习进度

4个模块

深入了解一个主题并学习基础知识。

22 条评论

中级等级

推荐体验

9 小时完成

灵活的计划

自行安排学习进度

您将学到什么

How patient experience data is used in the drug lifecycle
Developing a patient-centric measurement strategy and using qualitative and quantitative patient experience data as evidence in drug development
Common clinical outcome assessment outputs and considerations when interpreting clinical outcome assessment data

您将获得的技能

要了解的详细信息

可分享的证书

添加到您的领英档案

作业

12 项作业

授课语言：英语（English）

了解顶级公司的员工如何掌握热门技能

了解关于 Coursera for Business 的更多信息

Petrobras, TATA, Danone, Capgemini, P&G 和 L'Oreal 的徽标

该课程共有4个模块

The course is targeted toward people who are interested in how patient experience data and clinical outcome assessment (COA) data can be used as evidence across drug development, in the pharmaceutical industry. By the end of the course you will better understand how this data is collected and analysed to evidence how patients feel, function or survive in the context of a clinical trial. More specifically, the course will cover: i) a background to COAs; ii) a background to patient experience data; iii) how to select, develop/modify and validate COAs using qualitative data (a) and psychometrics (b); iv) interpreting data on a COA; v) measuring treatment related tolerability via patient reported outcomes; vi) Common COA data outputs.

This module will cover a background of clinical outcome assessments (COAs) and patient experience data, what they are and what they consist of, how this data fits into drug development and the importance of this data as evidence to the external environement (such as health authorities) across the drug lifecycle

涵盖的内容

6个视频3个作业1个插件

6个视频总计22分钟

New Video3分钟
1. Lesson introduction1分钟
2. Describe what a COA is5分钟
3. How COA evidence fits into the drug development process3分钟
4. External environment for COA science4分钟
A background to Patient Experience Data6分钟

3个作业总计40分钟

Module 1 assignment30分钟
An introduction to Clinical Outcome Assessments (COAs)5分钟
A background to Patient Experience Data and patient focussed drug development5分钟

1个插件总计94分钟

An overview from FDA on Patient Focussed Drug Development - First 94 minutes only94分钟

This Module will discuss ways in which qualitative research is used to select, develop, modify or validate a COA. The amount of qualitative research study teams need to conduct can depend on how much qualitative research for the concept of interest in the context of use is already publically available. Qualitative research is often an initial step health authorities such as FDA mandate when they evaluate the suitability of existing and newly developed COAs selected for a clinical trial

涵盖的内容

5个视频2篇阅读材料3个作业

5个视频总计36分钟

What qualitative evidence is needed by health authorities?9分钟
Steps 1 and 2: Qualitative literature reviews and Qualitative concept elicitation6分钟
Steps 3 and 4: Developing a disease conceptual model and reviewing existing COAs8分钟
Step 5: Adapt or develop a measure and conceptual frameworks5分钟
Step 6 and 7: Cognitively debriefing a new instrument and psychometric properties7分钟

2篇阅读材料总计60分钟

FDA PFDD guidance 2 - Methods to Identify What Is Important to Patients30分钟
Clinical Outcome Assessments: Conceptual Foundation–Report of the ISPOR Clinical Outcomes Assessment – Emerging Good Practices for Outcomes Research Task Force30分钟

3个作业总计41分钟

Module 2 assignment30分钟
An introduction to Clinical Outcome Assessments (COAs)6分钟
Understanding the steps involved in developing, selecting and modifying COAs5分钟

This Module will discuss some of the common quantitative methods used when selecting, developing, modifying and validating a COA. This will include a background to psychometrics and the different properties that are considered for classical test therory and item response theory. It will also touch on the important topic of evaluating change in a COA, what that change means and methods to establish what threshold in the COA of interest would be described as meaningful from the patient's point of view

涵盖的内容

11个视频1篇阅读材料3个作业

11个视频总计48分钟

1. Introduction to the lesson1分钟
2. What is psychometrics and why is it important?2分钟
3. Classical test theory (CTT)5分钟
4. Item response theory (IRT)7分钟
5. CTT vs IRT2分钟
6. Example setup and analysis plans3分钟
7. Examples of analyses7分钟
1. The value of establishing meaningful change in a COA3分钟
2. Approaches to establishing meaningful change in a COA3分钟
3. Primary and supportive methods for establishing meaningful change4分钟
4. An example of establishing meaningful change in Alzheimer's disease12分钟

1篇阅读材料总计30分钟

Development of the SMA independence scale–upper limb module (SMAIS–ULM): A novel scale for individuals with Type 2 and non-ambulant Type 3 SMA30分钟

3个作业总计40分钟

Module 3 assignment30分钟
Understanding psychometrics in COA development5分钟
COAs - establishing and interpreting meaningful change5分钟

This module will provide an understanding of a how patient reported outcomes (PROs) are used to measure treatment related tolerability, with a focus on a commonly used measure called the PRO-CTCAE as well as common COA outputs and considerations when interpreting COA data

涵盖的内容

7个视频2篇阅读材料3个作业

7个视频总计27分钟

1. Lesson introduction1分钟
2. PRO-CTCAE background and context3分钟
3. PRO-CTCAE items and scoring5分钟
4. PRO-CTCAE item selection3分钟
5. Reconciliation of PRO-CTCAE items3分钟
6. PRO-CTCAE Research examples3分钟
Interpreting and summarizing COA data in Clinical Study Reports8分钟

2篇阅读材料总计60分钟

Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials30分钟
FDA PFDD draft guidance 4 on Incorporating Clinical Outcome Assessments Into Endpoints For Regulatory Decision-Making30分钟